Test your knowledge of major biosimilar policies, including challenging regulatory frameworks from around the world.
Image credit: AA Studios - stock.adobe.com
Question 1: What term describes the regulatory pathway that allows biosimilars to be approved for indications not directly studied in clinical trials if they are scientifically justified?
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.